featured
2016 Top Stories in Metastatic Breast Cancer: CDK4/6 Inhibitors Change the Landscape of Treatment Options for ER+ Advanced Breast Cancer
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
-
Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res. 1962;18:387-414.
- Finn RS, Aleshin A, Slamon DJ, et al. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016. 18(1):17.
- Varma H, Skildum AJ, Conrad SE. Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells. PLoS One. 2007;2(12):e1256.
- Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25-35.
- Finn RS, Martin M, Rugo HS, et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 507.
- Cristofanilli M, Turner NC, Bondarenko, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-439.
- Dickler M, Tolaney SM, Rugo HS, et al. MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 510.
- Hortobagyi G, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer [published online October 7, 2016]. N Engl J Med. DOI: 10.1056/NEJMoa1609709.
Disclosure statements are available on the authors' profiles: